Shares in Astrazeneca have risen by over 5 per cent today after the drug giant flagged positive results from a late-stage trial for a treatment for prostate cancer.The FTSE 100 group said its Lynparza drug in combination with a common hormone therapy delayed disease progression by more than eight months compared to the current standard of care.'This Lynparza combination has the potential to afford first-line patients more time without disease progression while also maintaining their quality of life,' said Susan Galbraith, executive vice president of Oncology R&D at AstraZeneca.
Load More
Load More